Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients with insomnia

Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients with insomnia - Use-result survey to evaluate the safety and outcome of QUVIVIQ use in patients with insomnia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058402

Enrollment

500

Registered

2025-07-08

Start date

2025-07-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with insomnia treated with this drug

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Safety Adverse events(AE) Adverse Drug Reaction(ADR)	—

Secondary

Measure	Time frame
Efficacy sLSO(Subjective Latency to Sleep Onset) sTST(Subjective Total Sleep Time) sWASO(Subjective wake after sleep onset) Questions about sleeping and daytime symptoms as reported by the patients themselves Overall improvement	—

Countries

Japan

Contacts

Public Contactryoko suzuki

Nxera Pharma Japan Co.,Ltd Drug Safety,PMS

ryoko.suzuki@nxera.life03-5962-5718

Outcome results